Results 211 to 220 of about 938,469 (359)
Drug industry challenges government's action on generic statins [PDF]
, 2007 C. Dyer
openalex +1 more source
Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller +6 more
wiley +1 more source
Written drug promotion from pharmaceutical companies to general practitioners: adherence to regulations over two decades. [PDF]
Eur J Clin PharmacolAlmås G +3 more
europepmc +1 more source
Illegal Drug Usage and Industry [PDF]
American Association of Industrial Nurses Journal, 1967 openaire +2 more sources
Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley +1 more source
B2B Infrastructures in the Process of Drug Discovery and Healthcare
In this paper we describe a demonstration of an innovative B2B infrastructure which can be used to support collaborations in the pharmaceutical industry to achieve the drug discovery goal.
Boniface, M.J. +2 more
core
Kinetics for Drug Discovery: an industry-driven effort to target drug residence time
, 2017 Doris A. Schuetz +25 more
openalex +2 more sources